LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Pictilisib | 1.11 | uM | LJP6 | 72 | hr | 1235 | 2976 | 4405 | 0.6753 | 0.6140 |
MDA-MB-231 | Pictilisib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 2904 | 4405 | 0.6591 | 0.5928 |
MDA-MB-231 | Pictilisib | 10 | uM | LJP6 | 72 | hr | 1235 | 1869 | 4405 | 0.4245 | 0.2528 |
MDA-MB-231 | PD184352 | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4379 | 4660 | 0.9390 | 0.9346 |
MDA-MB-231 | PD184352 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4050 | 4660 | 0.8682 | 0.8568 |
MDA-MB-231 | PD184352 | 0.37 | uM | LJP5 | 72 | hr | 1235 | 3778 | 4660 | 0.8099 | 0.7905 |
MDA-MB-231 | PD184352 | 1.11 | uM | LJP5 | 72 | hr | 1235 | 3376 | 4660 | 0.7236 | 0.6880 |
MDA-MB-231 | PD184352 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 2937 | 4660 | 0.6293 | 0.5681 |
MDA-MB-231 | PD184352 | 10 | uM | LJP5 | 72 | hr | 1235 | 1449 | 4660 | 0.3105 | 0.0845 |
MDA-MB-231 | PLX-4720 | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4328 | 4660 | 0.9268 | 0.9198 |
MDA-MB-231 | PLX-4720 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4456 | 4660 | 0.9549 | 0.9512 |
MDA-MB-231 | PLX-4720 | 0.37 | uM | LJP5 | 72 | hr | 1235 | 4537 | 4660 | 0.9709 | 0.9663 |
MDA-MB-231 | PLX-4720 | 1.11 | uM | LJP5 | 72 | hr | 1235 | 4404 | 4660 | 0.9438 | 0.9394 |
MDA-MB-231 | PLX-4720 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4064 | 4660 | 0.8698 | 0.8567 |
MDA-MB-231 | PLX-4720 | 10 | uM | LJP5 | 72 | hr | 1235 | 3832 | 4660 | 0.8209 | 0.8015 |
MDA-MB-231 | Lapatinib | 0.04 | uM | LJP6 | 72 | hr | 1235 | 3964 | 4405 | 0.8995 | 0.8872 |
MDA-MB-231 | Lapatinib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4135 | 4405 | 0.9386 | 0.9319 |
MDA-MB-231 | Lapatinib | 0.37 | uM | LJP6 | 72 | hr | 1235 | 4253 | 4405 | 0.9655 | 0.9621 |
MDA-MB-231 | Lapatinib | 1.11 | uM | LJP6 | 72 | hr | 1235 | 4123 | 4405 | 0.9361 | 0.9293 |
MDA-MB-231 | Lapatinib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 4234 | 4405 | 0.9619 | 0.9585 |
MDA-MB-231 | Lapatinib | 10 | uM | LJP6 | 72 | hr | 1235 | 2602 | 4405 | 0.5916 | 0.5020 |
MDA-MB-231 | Sirolimus | 0.04 | uM | LJP6 | 72 | hr | 1235 | 3461 | 4405 | 0.7860 | 0.7536 |
MDA-MB-231 | Sirolimus | 0.12 | uM | LJP6 | 72 | hr | 1235 | 3485 | 4405 | 0.7920 | 0.7614 |
MDA-MB-231 | Sirolimus | 0.37 | uM | LJP6 | 72 | hr | 1235 | 3473 | 4405 | 0.7889 | 0.7574 |
MDA-MB-231 | Sirolimus | 1.11 | uM | LJP6 | 72 | hr | 1235 | 3535 | 4405 | 0.8036 | 0.7754 |